From [VOA Learning English]
Britain has approved Pfizer’s COVID-19 vaccine for emergency use.
英國批准輝瑞藥廠新冠肺炎疫苗緊急許可申請
看看我多久沒練習啦~~~
我發現要通順，要用口譯的腦去想才可以，不然都會被文字綁住 :(
Developed by the American drug-maker Pfizer and Germany’s BioNTech, it is the world’s first COVID-19 vaccine to complete a rigorous and scientific vaccine development process. China and Russia approved COVID-19 vaccines without waiting for results from large trials known as Phase 3 trials.
由美國輝瑞藥廠與德國BioNTech公司共同研發的新冠肺炎疫苗，將成為全球第一個通過嚴謹科學實驗程序的新冠肺炎疫苗。近期中國與俄羅斯所核准的肺炎疫苗，並沒有經過所謂的第三階段試驗，亦即大規模臨床實驗。
Britain’s Medicine and Healthcare Products Regulatory Agency (MHRA) said it used a “rolling review” to study as information became available from Pfizer during the trials. The process permitted the agency to approve the vaccine in a short amount of time.
英國醫藥保健產品管制局（MHRA）表示，他們使用「滾動式審查」檢驗輝瑞藥廠在試驗過程中不斷釋出的實驗報告，這個方法讓該局可以在短時間內核准使用新的疫苗。
The approval came just 12 days after Pfizer and BioNTech said they were requesting emergency use approval from regulatory agencies around the world. Final results from the large Phase 3 study found the vaccine to be 95 percent effective against COVID-19.
自輝瑞和BioNTech宣布他們已向全球各大藥品管制局提出疫苗許可申請後，才短短12天時間，申請即獲准通過。在第三階段的大規模試驗中，研究結果顯示這款疫苗對抗新冠肺炎展現高達百分之95的有效性。
Dr. June Raine, the chief executive of MHRA said, “The safety of the public will always come first.” She added, “And I emphasize again that this recommendation has only been given by the MHRA following the most rigorous scientific assessment of every piece of data.”
醫藥保健產品管制局的執行長珍‧芮恩強調：「民眾的安全永遠是我們的第一考量。這份核准建議是經過最嚴謹的科學程序，仔細評估每一份數據後才敢提出。」
British Health Secretary Matt Hancock told the British Broadcasting Corporation that “help is on its way.” He added, “When this vaccine is rolled out, things will get better. We will start that process next week.”
英國衛生部長麥特‧韓卡克在受訪時告訴英國廣播電視公司：「解藥就快來了。一旦疫苗開始生產，情況會馬上好轉。我們下星期就會開始執行生產計畫。」
The U.S. Food and Drug Administration (FDA) will meet on December 10 to consider Pfizer’s emergency use request. The agency will meet again on December 17 to look at American drug-maker Moderna’s emergency use request for its vaccine.
美國食品藥物管制局（FDA）也將在12月10日召開會議審查輝瑞的疫苗許可申請，隨後於12月17日，再審查美國製藥商默德納的申請。
Speaking on the U.S. television news program Good Morning America Wednesday, Dr. Moncef Slaoui said he “would expect the FDA to reach a similar conclusion” that British officials had reached. In other words, he expects the FDA to approve Pfizer’s request. Slaoui is head of the U.S. Operation Warp Speed program.
美國新冠肺炎疫苗開發計畫主持人莫契夫‧斯洛伊醫生，於週三在電視節目《早安美國》中預測食藥局也會做出與英國官方類似的決定，同意輝瑞的疫苗申請。
The European Medicines Agency said it has received emergency use requests from both Pfizer and Moderna. The agency added its decision “could be issued within weeks.”
歐盟藥物管制局也收到了輝瑞與莫德納的疫苗許可申請，並表示最快將再數週內作成決定。
British regulators are also considering another vaccine, developed by AstraZeneca and the University of Oxford.
此外，英國也正在關注另一款由 AstraZeneca與牛津大學研發的疫苗。
Who is first in line for the vaccine?
誰能最先接踵疫苗？
Britain said it would start vaccinating high-risk groups using 800,000 shots from Pfizer’s manufacturing center in Belgium early next week. The treatment requires two shots, which means about 400,000 Britons will receive the treatment this year. Pfizer has agreed to supply Britain with 40 million shots of vaccine through 2021.
針對高風險族群，英國將自下週起引進來自比利時生產的80萬劑輝瑞疫苗，由於該疫苗必須接踵兩次，估計將有40萬人得以在年底前接受施打。輝瑞已同意將再2021年提供40萬劑疫苗予英國使用。
“Age is by far the single most important factor in terms of risk from COVID-19,” said Wei Shen Lim, head of Britain’s COVID-19 vaccine committee.
「年齡是目前影響新冠肺炎風險指數的最主要因素。」英國新冠肺炎疫苗委員會主席魏珅林（音譯）指出。
In the United States, a government advisory group said Tuesday that health care workers and older people in nursing homes should be the first to receive the vaccine treatments. The U.S. is expected to receive 40 million shots of vaccine from Pfizer and Moderna by the end of this year, enough to vaccinate 20 million people.
The speed of the rollout will depend on how quickly Pfizer and BioNTech can manufacture the vaccine. The drug-makers said they are adding another manufacturing center in Germany, in addition to two already in Germany, one in Belgium and one in the U.S.
另一方面，美國政府顧問團則在星期二表示健康照護者與照護機構中的年長者應列入首批疫苗施打範圍。美國將在今年截止前收到來自輝瑞與莫德納共40萬劑疫苗，足夠讓20萬人接踵。
疫苗生產的速度取決於輝瑞與BioNTech的製造能力，兩間製藥公司表示他們將在原有的兩間德國廠、一間比利時廠以及一間美國廠外，再新一處德國製造中心。
The Pfizer-BioNTech vaccine must be stored and shipped at extremely cold temperatures of around minus 70 degrees Celsius. Pfizer said it has developed shipping containers that use dry ice to keep the vaccines cold. The containers are also equipped with GPS sensors to follow their movements.
輝瑞BioNtech的疫苗必須在攝氏零下70度的極端低溫中儲存運送，藥廠表示他們已經準備好搭載乾冰的貨櫃，使疫苗能低溫保存。貨櫃上亦裝有GPS感測器，以追蹤貨物的流向。
沒有留言:
張貼留言